£790.00

The 2025-2030 World Outlook for IBD (Ulcerative Colitis and Crohn's Disease) Treatments

Subjects

Price data last checked 19 day(s) ago - will refresh soon

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£790 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 72 days · 72 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 72 days • 1 price levels

Days at Price

Price Analysis

Most common price: £790 (72 days, 100.0%)

Price range: £790 - £790

Price levels: 1 different prices over 72 days

Description

This study covers the world outlook for IBD (ulcerative colitis and Crohn's disease) treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of IBD (ulcerative colitis and Crohn's disease) treatments as including all commonly understood services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AbbVie, Allergan, Biogen, Johnson & Johnson, Novartis, Pfizer, Takeda Pharmaceutical Company, UCB, and Valeant Pharmaceuticals International. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2024).

Product Specifications

Format: paperback
ASIN: B0CZLYNDD5
Category: Books > Subjects
Domain: Amazon UK
Release Date: 03 March 2024
Listed Since: 07 May 2024

The 2025-2030 World Outlook for IBD (Ulcerative Colitis and Crohn's Disease) Treatments

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2023-2028 Outlook for IBD (Ulcerative Colitis and Crohn's Disease) Treatments in China

The 2023 Report on IBD (Ulcerative Colitis and Crohn's Disease) Treatments: World Market Segmentation by City

The 2013-2018 Outlook for Inflammatory Bowel Disease Therapeutics in India

Ulcerative Colitis - Treatments, Special Populations and the Future

Ulcerative Colitis - Etiology, Diagnosis, Diet, Special Populations, and the Role of Interventional Endoscopy

The 2023-2028 Outlook for Ulcerative Proctitis in the United States

Management of Inflammatory Bowel Disease

Ulcerative Colitis from Genetics to Complications

CBT for Patients with Inflammatory Bowel Disease: A Treatment Manual

Inflammatory Bowel Disease: A Clinician's Guide

Inflammatory Bowel Disease: Pathogenesis, Diagnosis and Management (Clinical Gastroenterology)

Unveiling Ulcerative Colitis - A Comprehensive Approach to Understanding and Management

Inflammatory Bowel Disease: Diagnosis and Treatment

Inflammatory Bowel Disease

Biological Therapy for Inflammatory Bowel Disease

The 2013-2018 Outlook for Irritable Bowel Syndrome (IBS) Therapeutics in the United States

New Insights into Inflammatory Bowel Disease

Surgery for Crohn’s Disease, Second Edition (Digestive Diseases - Research and Clinical Developments)

Coping with Crohn’s and Colitis: A Patient and Clinician’s Guide to CBT for IBD

Chronisch-entzündliche Darmerkrankungen: in Klinik und Praxis

The 2023-2028 Outlook for Enteric Disease Testing-Treatment in the United States

The 2023-2028 Outlook for Enteric Disease Testing-Treatment in India

Gastrointestinal Inflammations and Gut Microbiota: Pathophysiology, Management, and Emerging Therapies

Inflammatory Bowel Disease and Irritable Bowel Syndrome